Inhibitex Inc.
This article was originally published in Start Up
Executive Summary
Preventing bacteria from initially binding to host tissue is an attractive strategy for prophylactic and therapeutic intervention in infectious diseases. Inhibitex Inc. thinks it can do just that, using its knowledge of microbial surface components recognizing adhesive matrix molecules (MSCRAMMs).
You may also be interested in...
Drug Resistance Start-Ups: Is Resistance Futile?
Overcoming drug resistance is a key goal of development--but will anyone fund it?
Understanding How To Develop BTK Inhibitors In MS Is Evolving
Having a reversible BTK inhibitor in the multiple sclerosis armamentarium could be the best way to favorably impact the treatment landscape.
Science Matters: Setting The Stage For Using Wearables In Oncology Drug Development
Digital biomarkers using data collected with wearable devices are making their way into clinical trials, largely in cardiovascular, respiratory and rare disease settings around physical activity metrics.